Academic literature on the topic 'VPS-39'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Contents
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'VPS-39.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "VPS-39"
1
Fong, Jiunn C. N., Khalid A. Syed, Karl E. Klose, and Fitnat H. Yildiz. "Role of Vibrio polysaccharide (vps) genes in VPS production, biofilm formation and Vibrio cholerae pathogenesis." Microbiology 156, no. 9 (September 1, 2010): 2757–69. http://dx.doi.org/10.1099/mic.0.040196-0.
Full textAbstract:
Biofilm formation enhances the survival and persistence of the facultative human pathogen Vibrio cholerae in natural ecosystems and its transmission during seasonal cholera outbreaks. A major component of the V. cholerae biofilm matrix is the Vibrio polysaccharide (VPS), which is essential for development of three-dimensional biofilm structures. The vps genes are clustered in two regions, the vps-I cluster (vpsU, vpsA–K, VC0916–27) and the vps-II cluster (vpsL–Q, VC0934–39), separated by an intergenic region containing the rbm gene cluster that encodes biofilm matrix proteins. In-frame deletions of the vps clusters and genes encoding matrix proteins drastically altered biofilm formation phenotypes. To determine which genes within the vps gene clusters are required for biofilm formation and VPS synthesis, we generated in-frame deletion mutants for all the vps genes. Many of these mutants exhibited reduced capacity to produce VPS and biofilms. Infant mouse colonization assays revealed that mutants lacking either vps clusters or rbmA (encoding secreted matrix protein RbmA) exhibited a defect in intestinal colonization compared to the wild-type. Understanding the roles of the various vps gene products will aid in the biochemical characterization of the VPS biosynthetic pathway and elucidate how vps gene products contribute to VPS biosynthesis, biofilm formation and virulence in V. cholerae.
2
Dawes, WJ, G. James, and K. Aquilina. "P94 Ventricular subgaleal shunting is a safe and effective temporising measure for the treatment of neonatal post haemorrhagic hydrocephalus." Journal of Neurology, Neurosurgery & Psychiatry 90, no. 3 (February 14, 2019): e47.1-e47. http://dx.doi.org/10.1136/jnnp-2019-abn.151.
Full textAbstract:
ObjectivesThe use of a temporising device to facilitate neonatal maturation prior to permanent ventricular peritoneal shunt (VPS) remains gold standard treatment for neonatal posthaemorrhagic hydrocephalus (PHH). The relative superiority of ventricular access device (VAD) or ventricular subgaleal shunt (VSG) remains contentious.DesignRetrospective case note review.Subjects49 neonates born between Sept 2012 to April 2018: (M:F 34:15); Average: gestation 26+3 (23 to 32+5); birth weight 870 g (±355 g); Papile grade 3:4 (ratio ≈ 1:2).MethodsComputer records from neonatal VSG at a single tertiary care children’s hospital reviewed.ResultsEarly complications associated with VSG seen in 13 cases (27%). Migration of shunt n=3, infection n=2, inadequate control of ventricular volume n=5, decompression haemorrhage n=2, wound leak n=1. All patients managed on NICU with an average inpatient stay of 5 days (range 2 to 15). 5 outcome groups defined: 1. Patient died (non neurological cause) (n=4) 2. VSG in situ for <1 year (n=7) 3. VSG and no VPS (n=6 16%) 4. VSG and VPS X1 never revised (n=17 45%) 5. VSG and VPS with revisions (n=15 39%) Rate of shunting in patients with VSG >1 year=84%. All patients that needed permanent VPS were operated within the first year. The average time elapsed prior to VPS was 86 days with over 80% of cases shunted within 100 days.ConclusionsVSG remains a safe method of temporary CSF drainage for the treatment of neonatal PHH with rates of shunting in line with the published literature.
3
Startsev, V. O., and A. V. Slavin. "CARBON AND GLASS REINFORCED POLYMER BASED ON SOLVENT-FREE BINDERS RESISTANCE TO THE IMPACT OF A MODERATE COLD AND MODERATE WARM CLIMATE." Proceedings of VIAM, no. 5 (2021): 114–26. http://dx.doi.org/10.18577/2307-6046-2021-0-5-114-126.
Full textAbstract:
In this work has been investigated the climatic resistance of carbon and fiberglass polymers for aviation purposes based on solvent-free binders VST-1208, VSE-1212, VSR-3M after 3 years of exposure of these materials in the moderate cold climate of Moscow and the moderate warm climate of Gelendzhik. The effect of destruction, post curing, plasticization of binders on the compressive and flexural strengths of carbon plastics VKU-27L, VKU-39, VKU-46 and fiberglass plastics VPS-47/7781, VPS-48/778 was determined using the methods of profilometry, moisture transfer and dynamic mechanical analysis. It is shown that while determining the state of PCM after climatic exposure, it is necessary to take into account the effects of the reversible plasticizing action of moisture. A comparison is made of the climatic resistance of the investigated materials.
4
Özcan, Işıl, Aslıhan Köroğlu, Ediz Kale, Tuncer Özçelik, and Burak Yilmaz. "Clinical evaluation of one-step impression technique and definitive casts." Balkan Journal of Dental Medicine 26, no. 2 (2022): 82–87. http://dx.doi.org/10.5937/bjdm2202082q.
Full textAbstract:
Background/Aim: The purpose of this study was to evaluate the quality of impressions made with vinyl polysiloxane (VPS) material in clinical conditions by using the one-step impression technique, and the quality of casts generated from these impressions. The effect of operator, number and location of abutments, and presence of bleeding were also investigated. Material and Methods: A total of 150 fixed dental prosthesis (FDP) impressions were taken and considered acceptable by 3 experienced prosthodontists in a clinic in an institutional setting. The impressions were evaluated and rated by another experienced prosthodontist and respective casts were evaluated and rated by an experienced dental technician using a digital microscope with ×200 magnification. The defects observed were noted as bubbles, voids, tears, or other defects. A scale was structured for the impressions and casts with ratings of Alpha (excellent; no defects), Bravo (acceptable; small defects), Charlie (inadequate; defects that require remaking of impression), and Delta (unacceptable; substantial defects at preparation finish lines). The data were analyzed with the Chi-square test for inter-operator, number of abutments, and location of prepared tooth variables (a=0.05). Results: The scale ratings were 85 Alpha (57%), 52 Bravo (34%), 6 Charlie (4%), and 7 Delta (5%) for the impressions, and 81 Alpha (54%), 58 Bravo (39%), 4 Charlie (3%), and 7 Delta (5%) for the respective casts. Sixty-nine percent of the impressions and respective casts were rated with the same score. The scale rating results were not influenced by inter-operator variability or number of abutments. Location of the prepared tooth was significant for anterior/posterior (p=0.04), but was not significant for maxilla/ mandible (p>0.05). Bleeding at the preparation site had a significant effect on the acceptability of the impression (p=0.003). Conclusions: The acceptability of VPS impressions using onestep technique was independent of the operator, number of abutments, or whether the prepared tooth was in maxilla or mandible. Impressions of teeth in the anterior region were more acceptable than those located in the posterior. Bleeding negatively affected the acceptability of the impressions. Clinicians may use VPS impressions for the fabrication of FDPs using onestep dual-phase technique. However, clinicians should carefully evaluate their impressions when bleeding is present when using this technique.
5
Ertaş, Murat, Derya Karaoğlu Gündoğdu, Mert Şahinoğlu, Ender Köktekir, and Hakan Karabağlı. "Effectiveness and success rates of endoscopic third ventriculostomy in patients under 2 years old." Sinir Sistemi Cerrahisi Dergisi 7, no. 2 (October 31, 2021): 67–71. http://dx.doi.org/10.54306/sscd.2021.08760.
Full textAbstract:
Objective: Endoscopic third ventriculostomy (ETV) stands out as an important option in the treatment of hydrocephalus without shunts. Endoscopic third ventriculostomy (ETV) has become more popular due to recent technical developments in endoscopic systems. But the urge of the physician, to provide a shuntfree survival for his patients, leads to performing the procedure in a unsuitable group of patients. Compared with shunt surgery, ETV presents a more physiological solution for the treatment of hydrocephalus. ETV is accepted as the first-line treatment method in many centers in appropriate cases in the treatment of obstructive hydrocephalus. The aim of this study is to examine the results of patients under the age of two underwent endoscopic third ventriculostomy. Methods: 79 patients who underwent ETV between 2011 and 2020 in our clinic and who were under 2 years of age at the time of operation were retrospectively analyzed. Results: 45 of 79 patients were male babies and 34 were female babies. The average age of the patients is 7 months (1 day - 22 months). In 39 (49.3%) patients, there was no need for repeat surgery in their follow-up after ETV. ETV procedure was repeated in 5 (6.3%) patients, and ventriluloperitoneal shunt (VPS) surgery was performed in 2 (2.5%) patients. In 13 patients, ventriculoperitoneal shunt was applied from the anterior and presented with shunt dysfunction. VPS surgery was not performed again after ETV in 3 (23%) of 13 patients after ETV. Conclusions: ETV can also be applied to patients younger than two years of age, and this treatment can give patients the chance to live a life independent of shunt.
6
Parikh, Kinjal, Donna L. Topping, Saee Dhoble, Jacob Cohen, Haleh Kadkhoda, Patrick Kugel, and Emily Sherene Van Laar. "Patient-centric care in bladder cancer: Virtual simulation to benefit clinical decision-making of oncologists." Journal of Clinical Oncology 39, no. 6_suppl (February 20, 2021): 492. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.492.
Full textAbstract:
492 Background: Immunotherapy (IO) utility in bladder cancer (UC) has expanded into multiple stages of disease. Employing IO optimally requires mastery of clinical trial data, patient eligibility criteria, and interpretation of biomarkers and determination of treatment sequencing. Given the nuanced therapeutic decision-making, education was developed in partnership between Medscape Oncology and Society for Immunotherapy of Cancer (SITC) to assist oncologists in improving their performance surrounding the management of patients with advanced UC. Methods: A virtual patient simulation (VPS) continuing medical education (CME)-certified activity depicting 2 advanced UC cases was made available to oncologist members of Medscape. The cases depicted 1) a patient with newly diagnosed metastatic UC with comorbidities and PDL1+ disease and 2) a patient with advanced UC progressing on platinum therapy with no actionable mutations. The VPS platform captures real-life decision making process of oncologists in an EHR-like format supported by an extensive database of diagnostic and treatment possibilities. Learners were able to interact with patients via video, order lab tests, assess patients, make diagnoses, and order treatments matching the scope and depth of actual practice. Tailored clinical guidance (CG) employing up-to-date evidence-based and faculty recommendations was provided after each decision point. Decisions were collected pre- and post-CG and analyzed using McNemar’s test to determine p-values. Data were collected from 4/28/20 to 7/13/20. Results: Analyses from oncologists (n = 51-66) found significant improvement in performance measured pre- to-post CG: Case 1: Ordering appropriate testing to determine patient eligibility for therapy (39% pre; 65% post; p < .001) Prescribing appropriate therapy based on patient- and disease-specific factors (38% pre; 77% post; p < .001) Providing appropriate counseling and follow-up for a patient receiving treatment (65% pre; 80% post; p < .01) Case 2: Ordering appropriate testing to determine patient eligibility for therapy (39% pre; 57% post; p < .01) Prescribing appropriate therapy based on patient- and disease-specific factors (25% pre; 41% post; p < .01) Providing appropriate counseling and follow-up for a patient receiving treatment (71% pre; 82% post; p < .05). Conclusions: This activity demonstrates the value of providing oncologists a simulation platform to practice and master clinical decision-making of the limitless possible diagnostic and therapeutic options in the management of advanced UC. Insights from rationales for each clinical decision point uncover continued gaps for oncologists on guideline recommendations, efficacy outcomes, or molecular implications. They also highlight barriers including limited experience or confidence with IO.
7
Pina, Yolanda, Brittany Evernden, Keiran Smalley, and Peter Forsyth. "23. RETROSPECTIVE REVIEW OF ADULT PATIENTS WITH LEPTOMENINGEAL DISEASE SECONDARY TO MELANOMA AT MOFFITT CANCER CENTER: DIAGNOSIS, TREATMENT AND OUTCOMES." Neuro-Oncology Advances 2, Supplement_2 (August 2020): ii4. http://dx.doi.org/10.1093/noajnl/vdaa073.013.
Full textAbstract:
Abstract BACKGROUND Nearly 5–8% of solid cancers present with leptomeningeal disease (LMD). Patients with LMD have a dismal prognosis with survival measured in weeks-to-months. The pathophysiology of this devastating disease remains unknown. METHODS A retrospective chart review was performed of twenty-five adult patients with LMD due to melanoma who were enrolled in the MCC 50172 clinical trial between 05/26/2015 and 07/17/2018. RESULTS Patients had a median age 63 years (31–80) at diagnosis with LMD. Sixteen had confirmed LMD and five did not meet criteria for LMD, but had positive cerebrospinal fluid (CSF)-circulating tumor cells (CTC’s). Those with LMD had a median KPS of 70 (30–90) at presentation, and symptoms most commonly included altered mentation n=6 (37%), headaches n=4 (25%), focal weakness n=3 (19%), and paresthesia n=2 (12%). Eleven patients were diagnosed by MRI. Ten patients (62%) had positive CSF cytology on first attempt and fourteen (87%) on first-two attempts. Lumbar puncture mean OP was 29.4 cmH2O (18–65), with CSF WBC 21.8/cumm (SD 25.6), RBC 2942.5/cumm (SD 9056.1), and protein 187.6 mg/dL (SD 166.1). CSF-CTC’s CellSearch analysis had a sensitivity of 0.75 (12[12 + 4]) and specificity of 0.44 (4[4 + 5]); PPV 0.71 and NPV 0.50. Twelve patients with LMD had positive CSF-CTC’s. Prior to LMD diagnosis, patients were treated with immune checkpoint inhibitors (ICI’s) n=9 (56%), BRAF+/-MEK inhibitors n=5 (31%), and/or RT n=5 (31%). Patients with LMD were treated with Ommaya n=13 +VPS n=3, WBRT n=7, ICI’s n=5, BRAF+MEK inhibitors n=4, and IT topotecan. LMD patients had a median survival 3.27 months after diagnosis (0.30–39). Two patients outlived their counterparts by 21.1 and 39.0 months. The 2 long-term survivors were treated with WBRT and either ICI, pembrolizumab or ipilimumab+nivolumab. CONCLUSION Clinical studies in LMD can provide critical insights and help to develop improved guidelines and current therapies.
8
Rauw, Jennifer Marie, Sunil Parimi, Nikita Ivanov, Jessica Noble, Eugenia Wu, Monita Sundar, Jennifer Goulart, and Celestia S. Higano. "The evolution of the education module for men with metastatic prostate cancer (mPC) in the prostate cancer supportive care (PCSC) program." Journal of Clinical Oncology 39, no. 28_suppl (October 1, 2021): 279. http://dx.doi.org/10.1200/jco.2020.39.28_suppl.279.
Full textAbstract:
279 Background: The PCSC Program was initiated in 2013 at the Vancouver Prostate Centre to provide a comprehensive program for patients and partners with prostate cancer. This program provides educational sessions (ES) and clinical services, including decision-making for primary therapy, sexual health, pelvic floor physiotherapy, hormone therapy, counseling, exercise, and nutrition for patients in BC, Canada. In 2016, the PCSC Program expanded to BC Cancer Victoria and in 2017 to other BC Cancer sites. In 2018, medical oncologists (MDs) in Victoria (JR, SP) developed an Education Module addressing treatment options for men with metastatic hormone sensitive (mHSPC) and metastatic castration resistant (mCRPC) disease. MDs delivered in-person ES in Victoria in 2018 and, in 2019, added a virtual platform (VP) option. From 3-5/2020, the ESs were on hold due to the COVID pandemic and parental leaves. In 6/2020, the ESs resumed only on VP, and the PCSC Oncology Nurse Practitioner (NP), NI, gave the presentations for the MDs on leave. In 10/2020, due to a changing standard of care for mHSPC, the PCSC team consolidated the two ESs into one. We report on the evolution of this Education Module in response to both the changing standard of care and the COVID pandemic. Methods: We prospectively collected attendance and patient characteristic metrics from all ES for men with mPC. We tracked presenter type (MD vs. NP) and prospectively collected anonymous patient satisfaction questionnaires. Results: From 1/2018 to 1/2021, 100 men registered for 27 ES; 81 men, 41 partners, and 2 family members actually attended. 48/75 (64%) men were white, 39/75 (52%) retired, and 56/75 (74.7%) married. 47 men attended 12 mHSPC ES, 13 men attended ten mCRPC ES, and 17 attended four consolidated ES. MDs presented 15 ES, and the NP presented 12 ES. Responses to questions on 70 satisfaction surveys were similar for MD vs. NP presenters. 9 responders to the recently added VP-specific questions said they agreed (4) or strongly agreed (5) that it was beneficial to watch the ES at home on a computer. The Table below shows attendance per site per year. Conclusions: The ESs for men with mPC were well-received. Although there was a VP option before COVID, attendance increased significantly after the lockdown as patients and providers became more familiar with VPs. Satisfaction surveys confirmed that an NP could deliver the ES rather than MD. Consolidation of the mHSPC and mCRPC ES reflected the changing standard of care and resulted in more efficient use of presenter time. Virtual delivery of the sessions provided greater access to those living in distant or remote areas of the province and those in lockdown during the COVID pandemic. [Table: see text]
9
Li, Min, Jia Liu, Xuhui Deng, Qingzhou Gan, Yijie Wang, Xiaofeng Xu, Ying Jiang, and Fuhua Peng. "Triple therapy combined with ventriculoperitoneal shunts can improve neurological function and shorten hospitalization time in non-HIV cryptococcal meningitis patients with increased intracranial pressure." BMC Infectious Diseases 20, no. 1 (November 16, 2020). http://dx.doi.org/10.1186/s12879-020-05510-9.
Full textAbstract:
Abstract Background Raised intracranial pressure (ICP) and insufficient antifungal regimens are the two main factors result to unsatisfactory outcomes in non-HIV cryptococcal meningitis (CM) patients. In this study, we try to discuss that whether triple therapy of amphotericin B (AmB), fluconazole, 5-flucytosine (5-FC) plus ventriculoperitoneal shunts (VPS) is superior to AmB, 5-FC, fluconazole plus intermittent lumbar puncture in induction therapy in non-HIV CM patients with increased ICP. Methods We reviewed 66 clinical records from non-HIV CM patients with increased ICP. The demographic and clinical characteristics, BMRC staging, cerebrospinal fluid profiles (CSF), brain magnetic resonance imaging, treatment, and outcomes of these individuals were retrospectively analyzed. All non-HIV CM patients with increased ICP (≥ 25 cmH2O) were divided into two groups, including 27 patients treated with triple antifungal agents and 39 patients treated with the same triple therapy plus VPS. Results Triple therapy plus VPS group had more satisfactory outcomes, more CSF sterilization at 10 weeks follow-up, lower CSF opening pressure, lower BMRC staging scores one week after VPS, less CSF C. neoformans counts and CSF culture positive. Besides, these patients had shorter hospital stay than triple therapy group. Conclusions Triple antifungal agents combined with VPS could effectively reduce ICP, had faster rate of clearance of C. neoformans counts, more improved neurological function, shorten hospitalization time and better outcomes in non-HIV CM patients with increased ICP. Our study indicated that triple therapy plus early VPS may be an optimal treatment for non-HIV CM patients with increased ICP.
10
Gonzalez, Wendy, Elyse Forman, Christoph Stretz, Nicholas S. Potter, Linda C. Wendell, Michael Reznik, Karen L. Furie, Bradford Thompson, and Ali Mahta. "Abstract TP113: Association Of External Ventricular Drain Duration And Outcomes In Aneurysmal Subarachnoid Hemorrhage." Stroke 53, Suppl_1 (February 2022). http://dx.doi.org/10.1161/str.53.suppl_1.tp113.
Full textAbstract:
Introduction: Hydrocephalus is a common complication following aneurysmal subarachnoid hemorrhage (aSAH) and is usually treated with external ventricular drain (EVD). However, there is no consensus on EVD weaning process and duration of cerebrospinal fluid (CSF) drainage. We aimed to determine association of EVD duration and outcomes. Methods: We performed a retrospective cohort study of consecutive patients with aSAH who were admitted to an academic referral center between 2016 and 2021. Binary logistic regression was used to test the association of EVD duration (continuous variable) and outcomes including functional outcome defined as modified Rankin scale of 4-6 at 3 months after discharge and requirement for ventriculoperitoneal shunt (VPS) placement. Multiple linear regression analysis was used to test the association of EVD duration and hospital length of stay (both continuous variables) Results: Of 316 patients with aSAH, 253 patients received external ventricular drain (EVD) on admission for symptomatic hydrocephalus and we included survivors (n=204) in final analysis. (mean age 57.9 years (SD 13.8), 62% female, 71% white). VPS was placed in 15% (30/204) prior to hospital discharge. Duration of EVD was longer in patients with worse functional outcome (median 18 days [IQR 13.5-23] vs 12 days [IQR 8-19); p=0.006). EVD wean was interrupted in 39% of survivors (80/204) due to persistent hydrocephalus (61%) and asymptomatic vasospasm (19%) based on transcranial Doppler criteria. Longer EVD duration was associated with higher VPS requirement (odds ratio 1.17 per day, 95% CI 1.09-1.26; p<0.001) after adjustment for age, aneurysm related factors, Hunt and Hess grades, modified Fisher scales and delayed cerebral ischemia. EVD related complications such as infections (2%) and tract hemorrhage (9%) were non-significantly higher in patients with longer EVD duration. (p=0.070) Longer EVD duration was associated with longer hospital length of stay (0.88 more days, 95% CI 0.73-1.04; p<0.001) independent of aSAH complications. Conclusions: Longer EVD duration can be associated with worse outcomes and higher need for VPS placement and longer hospital length of stay. Further studies are needed to justify early VPS placement in selected patients.